TABLE 3.
In vitro antifungal agent susceptibilities of Candida isolates collected by the SENTRY Program in 2006 to 2007
| Species (no. tested) | No. (%) of isolates or MIC50/90 in μg/ml (% susceptible)a
|
||
|---|---|---|---|
| North America | Europe | Latin America | |
| All Candida spp. | 726 (50.1) | 429 (29.6) | 274 (18.9) |
| Anidulafungin | 0.03/2 (98.9) | 0.03/1 (99.3) | 0.03/1 (98.5) |
| Caspofungin | 0.12/0.5 (99.7) | 0.12/0.5 (100.0) | 0.12/0.5 (99.6) |
| Amphotericin B | 0.5/1 (99.9) | 0.5/1 (99.5) | 1/1 (98.9) |
| 5-FC | ≤0.5/≤0.5 (95.7) | ≤0.5/≤0.5 (95.3) | ≤0.5/≤0.5 (97.1) |
| Fluconazole | ≤0.5/8 (91.3) | ≤0.5/8 (94.4) | ≤0.5/2 (97.1) |
| Itraconazole | 0.06/1 (64.9) | 0.06/1 (72.3) | 0.06/0.5 (68.6) |
| Posaconazole | ≤0.06/1 | ≤0.06/1 | ≤0.06/0.25 |
| Voriconazole | ≤0.06/0.25 (97.9) | ≤0.06/0.25 (98.4) | ≤0.06/≤0.06 (99.3) |
| C. albicans | 377 (48.9) | 260 (33.7) | 126 (16.3) |
| Anidulafungin | 0.015/0.06 (100.0) | 0.015/0.06 (100.0) | 0.015/0.06 (100.0) |
| Caspofungin | 0.12/0.25 (100.0) | 0.12/0.25 (100.0) | 0.12/0.25 (100.0) |
| Amphotericin B | 0.5/1 (100.0) | 0.5/1 (100.0) | 0.5/1 (100.0) |
| 5-FC | ≤0.5/≤0.5 (96.8) | ≤0.5/≤0.5 (98.8) | ≤0.5/≤0.5 (99.2) |
| Fluconazole | ≤0.5/≤0.5 (99.5) | ≤0.5/≤0.5 (100.0) | ≤0.5/≤0.5(100.0) |
| Itraconazole | 0.03/0.12 (97.3) | 0.03/0.06 (98.1) | 0.03/0.12 (97.6) |
| Posaconazole | ≤0.06/0.12 | ≤0.06/≤0.06 | ≤0.06/0.12 |
| Voriconazole | ≤0.06/≤0.06 (100.0) | ≤0.06/≤0.06 (100.0) | ≤0.06/≤0.06 (100.0) |
| C. parapsilosis | 122 (51.3) | 53 (22.3) | 60 (25.2) |
| Anidulafungin | 2/2 (93.4) | 2/2 (94.3) | 1/2 (98.3) |
| Caspofungin | 0.5/1 (99.2) | 0.5/1 (100.0) | 0.5/1 (100.0) |
| Amphotericin B | 1/1 (100.0) | 1/1 (100.0) | 1/1 (100.0) |
| 5-FC | ≤0.5/≤0.5 (99.2) | ≤0.5/≤0.5 (100.0) | ≤0.5/≤0.5 (96.7) |
| Fluconazole | 1/4 (95.9) | 1/2 (100.0) | 1/4 (95.0) |
| Itraconazole | 0.25/0.5 (43.4) | 0.25/0.25 (43.4) | 0.25/0.5 (30.0) |
| Posaconazole | 0.12/0.25 | 0.12/0.25 | 0.12/0.25 |
| Voriconazole | ≤0.06/0.12 (100.0) | ≤0.06/≤0.06(100.0) | ≤0.06/0.12 (98.3) |
| C. glabrata | 133 (65.8) | 57 (28.2) | 11 (0.05) |
| Anidulafungin | 0.06/0.12 (100.0) | 0.06/0.12 (100.0) | 0.06/0.12 (100.0) |
| Caspofungin | 0.12/0.25 (100.0) | 0.25/0.25 (100.0) | 0.25/0.5 (100.0) |
| Amphotericin B | 1/1 (100.0) | 1/1 (100.0) | 1/1 (100.0) |
| 5-FC | ≤0.5/≤0.5 (100.0) | ≤0.5/≤0.5 (100.0) | ≤0.5/≤0.5 (100.0) |
| Fluconazole | 8/>64 (71.4) | 8/16 (78.9) | 4/16 (81.8) |
| Itraconazole | 1/>2 (2.3) | 1/>2 (5.3) | 1/2 (9.1) |
| Posaconazole | 1/4 | 1/4 | 0.5/1 |
| Voriconazole | 0.25/2 (88.7) | 0.25/1 (93.0) | 0.12/0.5 (90.9) |
| C. tropicalis | 53 (33.7) | 36 (22.9) | 62 (39.5) |
| Anidulafungin | 0.03/0.06 (100.0) | 0.03/0.6 (100.0) | 0.03/0.06 (100.0) |
| Caspofungin | 0.12/0.5 (100.0) | 0.12/0.25 (100.0) | 0.12/0.5 (100.0) |
| Amphotericin B | 1/1 (100.0) | 1/1 (100.0) | 1/1 (95.2) |
| 5-FC | ≤0.5/≤0.5 (96.2) | ≤0.5/≤0.5 (91.7) | ≤0.5/≤0.5 (95.2) |
| Fluconazole | ≤0.5/1 (100.0) | ≤0.5/1 (97.2) | ≤0.5/≤0.5 (100.0) |
| Itraconazole | 0.12/0.5 (62.3) | 0.12/0.5 (72.2) | 0.12/0.5 (66.1) |
| Posaconazole | 0.12/0.25 | ≤0.06/0.25 | 0.12/0.25 |
| Voriconazole | ≤0.06/≤0.06 (100.0) | ≤0.06/≤0.06 (100.0) | ≤0.06/≤0.06 (100.0) |
a
The breakpoint criteria used are those of the CLSI (2008). When testing amphotericin B, a susceptibility breakpoint of ≤1 μg/ml was used. No results are shown for categories with <10 isolates.